RCMI Coordinating Center (RCMI CC) Header Logo

Connection

James Chambers to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications James Chambers has written about Antineoplastic Agents.
James Chambers
Connection Strength
0.028
Antineoplastic Agents
  1. Eto S, Saeki K, Yoshitake R, Yoshimoto S, Shinada M, Ikeda N, Kamoto S, Tanaka Y, Kato D, Maeda S, Tsuboi M, Chambers J, Uchida K, Nishimura R, Nakagawa T. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. PLoS One. 2019; 14(6):e0218382.
    View in: PubMed
    Score: 0.021
  2. Moore DJ, Chambers JK, Murdock PR, Emson PC. Human Ntera-2/D1 neuronal progenitor cells endogenously express a functional P2Y1 receptor. Neuropharmacology. 2002 Nov; 43(6):966-78.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support